Judge denies U.S. bid to stop UnitedHealth plan to buy Change

2 minute read

The corporate logo of the UnitedHealth Group appears on the side of one of their office buildings in Santa Ana, California, U.S., April 13, 2020. REUTERS/Mike Blake/File Photo

Register now for FREE unlimited access to Reuters.com

WASHINGTON, Sept 19 (Reuters) - A U.S. judge on Monday denied the Justice Department's bid to stop UnitedHealth Group (UNH.N) from buying Change Healthcare (CHNG.O), in a blow to the U.S. administration's tougher enforcement of antitrust issues.

Change shares rose 7% after the close of trading.

The Justice Department had filed a lawsuit in February aimed at stopping the $8 billion acquisition, saying the deal would give the largest U.S. health insurer access to its competitors' data and ultimately push up healthcare costs.

Register now for FREE unlimited access to Reuters.com

The department's top antitrust official, Jonathan Kanter, said they are "reviewing the opinion closely to evaluate next steps".

UnitedHealth announced the all-cash deal in January 2021, saying it would help streamline administrative and payment processes.

Judge Carl Nichols said in a brief order on Monday that he would deny the government's request to stop the deal, and ordered the companies to go forward with an asset sale that they had proposed.

The order follows a trial in the case in August in the U.S. District Court for the District of Columbia.

UnitedHealth said it was "pleased with the decision" and looked forward to combining with Change as quickly as possible.

The Justice Department had said that UnitedHealth and Change Healthcare offer competing software for processing healthcare claims and together serve 38 of the top-40 health insurers in the country.

The department argued that access to the claims would give UnitedHealth a view into rivals' health plans, including Humana Inc (HUM.N), Anthem Inc and others.

The loss for the Justice Department follows a recent decision by a Federal Trade Commission judge that genetic analysis equipment maker Illumina should be allowed to buy cancer detection test maker Grail - a move opposed by the agency. read more

The Justice Department also lost a bid to win convictions of executives at chicken processing companies that it accused of price-fixing. read more

But the agencies have also had wins, and successfully killed planned deals by Aon Plc and Willis Towers Watson Plc as well as Lockheed Martin's plan to buy engine maker Aerojet Rocketdyne.

Register now for FREE unlimited access to Reuters.com
Reporting by Diane Bartz; editing by Jonathan Oatis, Deepa Babington and Christian Schmollinger

Our Standards: The Thomson Reuters Trust Principles.

Thomson Reuters

Focused on U.S. antitrust as well as corporate regulation and legislation, with experience involving covering war in Bosnia, elections in Mexico and Nicaragua, as well as stories from Brazil, Chile, Cuba, El Salvador, Nigeria and Peru.